EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies

Aybüke Züleyha Kaya iD, Asaf Evrim Evren iD, Gülşen Akalın-Çiftçi iD, Leyla Yurttaş iD

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70338 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2026. Written by Aybüke Züleyha Kaya and 3 co-authors. Institution: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Anadolu University, Eskisehir, Turkey. Major MEDLINE topics: Quinazolinones, Protein Kinase Inhibitors, Drug Design, Antineoplastic Agents. Cited 1 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY 4.0). Funded by: Anadolu Üniversitesi.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cancer is one of the most seen diseases worldwide. Due to the serious side effects of anticancer drugs and toxic effects on healthy cells, investigations for novel anticancer agents with low side effects have become one of the most important research areas of our age. With this objective, 17 new compounds were designed and successfully synthesized based on the quinazolinone, which is commonly found in the structures of FDA‐approved EGFR inhibitors, and their structures were elucidated by IR, HRMS, 1 H, and 13 C‐NMR spectral analysis methods. According to cytotoxicity test results, it was determined that compound 4j showed high inhibitory activity compared to cisplatin and gefitinib in the A549 cell line. In apoptosis induction studies, it was observed that compounds 4a , 4b , 4d , and 4f showed activity in the A549 cell line, while compound 4j showed activity in the MCF‐7 cell line. In the study investigating caspase‐3 activation, compounds 4a , 4m , and 4o were found active in the A549 cell line, while compounds 4a and 4o were found active in MCF‐7 cells. In EGFR enzyme inhibition studies, it was observed that the activities of molecules 4b , 4f , and 4j were higher than gefitinib. In silico studies indicated that 4j interacted by establishing significant bonds with both caspase‐3 and EGFR enzyme.

Subjects

MeSH terms (MEDLINE)

QuinazolinonesProtein Kinase InhibitorsDrug DesignAntineoplastic AgentsHumansErbB ReceptorsApoptosisMolecular Docking SimulationCaspase 3A549 CellsMCF-7 CellsCell Line, TumorStructure-Activity RelationshipGefitinib

Author keywords

EGFR inhibitionanticancerapoptosis inductioncaspase‐3 enzyme inhibitionmolecular dynamics simulationsquinazolinone

Substances

ErbB ReceptorsQuinazolinonesProtein Kinase InhibitorsAntineoplastic AgentsCaspase 3EGFR protein, humanGefitinib

Authors and institutions

  • Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Anadolu University, Eskisehir, Turkey.
  • Institute of Graduate Education, Anadolu University, Eskisehir, Turkey.
  • Faculty of Pharmacy, Department of Biochemistry, Anadolu University, Eskisehir, Turkey.

ORCID profiles: Aybüke Züleyha Kaya, Asaf Evrim Evren, Gülşen Akalın-Çiftçi, Leyla Yurttaş

Funding

  • Anadolu Üniversitesi

Cite

APA

Kaya, A. Z., Evren, A. E., Akalın-Çiftçi, G., & Yurttaş, L. (2026). Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70338

Vancouver

Kaya AZ, Evren AE, Akalın-Çiftçi G, Yurttaş L. Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70338

BibTeX
@article{Kaya2026,
  author = {Kaya, Aybüke Züleyha and Evren, Asaf Evrim and Akalın-Çiftçi, Gülşen and Yurttaş, Leyla},
  title = {Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70338}
}
Start for free →